Thank you. Lenny?
Thank you very much, Tom. During the second quarter, we made steady progress across our strategic objectives for the year, as we continue to expand our initiatives to develop and deliver life-transforming therapies for patients with severe and ultra-rare disorders.
Our development and commercial teams performed solidly in three key areas during the quarter. First, we again provided Soliris to a substantial number of new patients with PNH. Second, we are very pleased with the ongoing launch in aHUS as we continue to serve an increasing number of patients with Soliris. And finally, we continue to advance our eight lead development programs, comprising the most robust pipeline in our company’s history.
I’d like to start with a review of our operations in the United States. With regard to aHUS during Q2, we made significant progress in serving an increasing number of patients. Our field team continued to expand our aHUS disease education programs to both hematologists and nephrologists, resulting in a meaningful increase in the number of aHUS patients who initiated treatment with Soliris.
Although we expect the uptake of Soliris in aHUS to continue to be limited by the relatively low prevalence to the disease, we are nonetheless encouraged by the progress that we are making as we identify and serve an increasing number children and adults with this severe and life-threatening disorder.
Turning to PNH. Our expanded presence among hematologists again resulted in a growing positive impact on patient care. We continued to observe that as more patients are being tested, those who are diagnosed with PNH are also starting on Soliris rapidly, reflecting their physician’s understanding of the life-threatening severity of PNH and the role of Soliris to transform their patient’s lives. In our PNH operations beyond the United States, our quarter-on-quarter growth reflects the addition of a steady number of new Soliris patients with PNH in our core country Southern Europe, as well as in Japan.